the new-aeds, whose developments were motivated following the discovery of the valproate and its marketing in the u.s in 1978, have presented more therapeutic options. there are approximately twenty four fda-approved antiepileptic drugs for use in patients with epilepsy, five of which were identified and have come on to the market between 2009 and 2012. the new-aeds are of interest, not due to ...

This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-Coxibs) in pharmacological treatment airway inflammation Cystic Fibrosis (CF). Our research group developed several classes NO-Coxibs arthritis, and among them compounds showed an outstanding vivo efficacy good pharmacokinetic properties. The antiinflammatory properties displayed by these during p...

background: vancomycin is used abundantly in patients undergoing hsct, especially during neutropenic fever. despite its widespread use little is known about vancomycin pharmacokinetics in hsct patients. we conducted this study to investigate vancomycin pharmacokinetic parameters in our hsct patients and to evaluate current dosing regimen based on trough vancomycin concentrations measurement. me...

Nanoformulations have become important tools for modifying drug disposition, be it from the perspective of enabling prolonged drug release, protecting the drug molecule from metabolism, or achieving targeted delivery. When examining the in vivo pharmacokinetic properties of these formulations, most investigations either focus on systemic concentrations of total (encapsulated plus unencapsulated...

the pharmacokinetic parameters of domestic and imported ranitidine hydrochloride tablets (ranitidine, formulated and manufactured by kharazmi pharmaceuticals, iran, and zantac ? manufactured by glaxo, uk) were measured in 14 healthy subjects following oral administration of a single 300-mg dose of each brand and compared for bioequivalence evaluation. the pharmaceutical equivalency of both form...